Shenzhen Xijiya Biotechnology Co., Ltd. (hereinafter referred to as "Xijiya") conducts semi-rational design through its proprietary Zymevolver@ strain construction technology and enzyme engineering evolution platform, developing a new generation of precise and highly effective anti-aging molecules.

 In the existing enzyme library, the types and quantities of biological enzymes can cover conventional biocatalytic reaction pathways. The team is proficient in constructing cell factories based on Escherichia coli, yeast, and other chassis, which are applied to multi-scenario biosynthesis. The technical platform covers genetic engineering, metabolic engineering, enzyme engineering, fermentation engineering, and chemical synthesis. Xijia has been rated as a specialized, refined, unique, and innovative enterprise, a national high-tech enterprise, a technology-based SME, an innovative SME, and a synthetic biology enterprise. It has participated in 3 group standards, 2 software copyrights, and 10 authorized invention patents, with multiple invention patents in the substantive examination stage. The company is actively preparing for the national-level Little Giant program.

 Our products have been certified by multiple authoritative third-party testing institutions, including MicroQualityLab in the United States, JFRL in Japan, SGS, Intertek, and others.

 Corporate website: https://www.hygieiabiotech.com/